Back to dashboard
CommercialAdministrativeLow impact

[New York] Lenalidomide is now available with end‑to‑end REMS support

Anthem BCBS·NY · Oncology, Hematology·Provider Bulletin
Effective date
Not stated
We identified it
May 3, 2026
Days to comply
—

Summary

Anthem New York now provides end-to-end REMS (Risk Evaluation and Mitigation Strategy) support for lenalidomide, a cancer medication. This streamlines the complex safety monitoring and dispensing process for providers prescribing this high-risk oncology drug.

Action Required

Action needed
Oncology practices prescribing lenalidomide should contact Anthem New York to understand the new REMS support process and how it may streamline patient access and safety monitoring requirements.

Related policy hubs